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Aims: This subgroup analysis of the A1chieve study examined data from 15,545 people who
started treatment with insulin detemir ± oral glucose-lowering drugs in routine clinical
care.
Methods: A1chieve was a 24-week, international, prospective, non-interventional study of
people with type 2 diabetes from non-Western nations starting treatment with basal in-
sulin detemir, bolus insulin aspart or biphasic insulin aspart 30, alone or in combination,
to evaluate their safety and effectiveness in routine clinical practice.
Results: HbA1c for the global cohort improved after 24 weeks from 9.5 ± 1.6% by −2.0 ± 1.6%
[80 ± 17 by −22 ± 17 mmol/mol] (−2.1 ± 1.6% [−23 ± 17 mmol/mol] for insulin-naïve partici-
pants; −1.6 ± 1.7% [−17 ± 19 mmol/mol] for prior insulin users). Fasting plasma glucose and
postprandial plasma glucose were also signiﬁcantly reduced (p< 0.001), irrespective of prior
therapy or geographical region. The incidence of major hypoglycaemia decreased signiﬁ-
cantly over 24 weeks in both the insulin-naïve and insulin-experienced groups (p< 0.0001).
Mean body weight decreased overall by −0.4 ± 4.0 kg and blood pressure, lipid proﬁles, and
self-reported quality of life improved over 24 weeks for all people starting treatment with
insulin detemir.
Conclusion: Peoplewith type 2 diabetes in poor glycaemic control starting treatment with in-
sulin detemir reported signiﬁcant improvements in glycaemic control with improved treat-
ment tolerability, irrespective of prior treatment and geographical region, after 24 weeks.
1. Introduction
The primary aim of diabetes management is to achieve sat-
isfactory levels of glycaemic control, thereby reducing the
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risk of serious long-term diabetes related complications
[1–3]. Published data, however, suggest that the majority
of people with type 2 diabetes (T2D) worldwide are not
achieving the recommended targets set for good glycaemic
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control [4–8]. The progressive loss of beta-cell function that
characterises T2D ideally requires concurrent changes in
treatment to allow people to reach and then maintain ad-
equate glycaemic control and most will require insulin ther-
apy to achieve this [9,10]. Currently, insulin analogues are
gaining wide acceptance and are frequently prescribed due
to their distinguished pharmacodynamic and pharmacoki-
netic proﬁle and based on evidence of their effectiveness
and safety in clinical trials [11], yet effectual use in the
management of glycaemia remains a challenge, particularly
in developing countries where there is a sustained rise in
prevalence of diabetes.
The introduction of basal insulin is a simple, effective
and well-validated choice to start people with T2D on in-
sulin therapy [12,13]. Randomised controlled trials (RCTs)
have shown that the basal analogue insulin detemir can
effectively improve glycaemic control with a lower risk of hy-
poglycaemia than with intermediate-acting human insulin
NPH [14–17], and is associated with less weight gain than
NPH and the basal insulin analogue glargine [14,15,17,18].
Complementary evidence from real-life clinical practice in
large heterogeneous populations provides further support
for the clinical beneﬁts that insulin detemir may offer for
insulin-naïve patients with T2D starting basal therapy and
for those changing treatment from existing insulin treat-
ment (efﬁcacy, lower risk of hypoglycaemia and less weight
gain) [7,12,14,19,20].
A1chieve was an observational study designed to examine
the safety and clinical effectiveness of insulin analogues in
T2D. The global scope of A1chieve, which included 28 coun-
tries with different healthcare resources and ethnic diversity,
allows insights into regional and country effects on clinical
outcomes. The aim of this sub-group analysis is to exam-
ine data from people who started treatment with insulin
detemir ± oral glucose-lowering drugs (OGLDs) in routine
clinical care. Outcomes from patients on different pre-study
therapies are compared, along with regional differences.
2. Methods
2.1. Study design
A1chieve was a 24-week, international, prospective, mul-
ticentre, non-interventional study of people with T2D who
had started using basal insulin detemir, bolus insulin as-
part or biphasic insulin aspart 30 alone or in combination,
to evaluate their safety and effectiveness in routine clinical
practice [7,21]. The study was carried out in 28 countries
across Asia, Africa, Latin America and Europe, grouped into
seven geographical regions: China, South Asia, East Asia,
North Africa, Middle East/Gulf, Latin America and Russia. A
total of 66,726 people participated in the study from 3166
clinical sites, recruited between January 2009 and June 2010.
2.2. Participants and treatment
Clinical outcomes are reported here for people with T2D
who were prescribed insulin detemir by their physician in
the course of normal clinical practice. They were eligible for
enrolment provided prior pharmaceutical therapy did not in-
clude exposure to the study insulins for >4 weeks prior to
acceptance. Patients with a hypersensitivity to the study
drug or the excipients, and women who were pregnant,
breastfeeding, or had the intention of becoming pregnant
within the next 24 weeks were excluded from the study.
When prescribed, insulin detemir was commercially avail-
able and was funded according to local practice in routine
care. The selection of patients and any changes to dose and
concomitant therapy were made at the discretion of the
participant and consulting physician. Ethical approval was
obtained in each country.
2.3. Assessments and outcome measures
The primary safety assessment was evaluation of the in-
cidence of serious adverse drug reactions (SADRs), including
major hypoglycaemic events, considered related to insulin
detemir between baseline and ﬁnal visit. Secondary safety
assessments included the change in number of hypogly-
caemic events in the last 4 weeks before the interim and
ﬁnal visits (approximately 12 and 24 weeks from baseline),
compared with the last 4 weeks before the baseline visit, and
the number of adverse drug reactions (ADRs) from baseline
to ﬁnal visit.
Effectiveness assessments were change in HbA1c, fast-
ing plasma glucose (FPG), postprandial plasma glucose (PPG),
and body weight between baseline and interim and ﬁnal
visits, and change in systolic blood pressure (SBP) and lipid
proﬁle at ﬁnal visit. Assessments were recorded by physi-
cians during routine clinical visits and data were collected
from medical records, patient diaries, and recall, and labo-
ratory measurements were made in local laboratories. The
physician’s rationale for prescribing insulin detemir was also
recorded.
Health-related quality of life (HRQoL) was measured using
the EQ-5D questionnaire [22] at baseline and after 24 weeks
of therapy. This questionnaire was designed to assess mo-
bility, self-care, usual activities, pain/discomfort, and anxi-
ety/depression and provides a visual analogue scale (VAS) for
individuals to rate their current HRQoL between 0 and 100,
with a higher score indicating better self-perceived health.
Full study design details, assessments, and outcome mea-
sures have been published previously [7].
2.4. Statistical methods
Analysis of safety and efﬁcacy outcomes was performed
on any participant entered into the study who had data
relevant to that analysis. Analyses were performed for the
entire cohort prescribed insulin detemir, categorised by prior
insulin-treated or insulin-naïve and by geographical regions
(deﬁned in study design). Comparison between pre-study
therapy and regions are reported as descriptive statistics
only. Changes from baseline for HbA1c, FPG, PPG, lipids, and
QoL were analysed using a paired t-test, with the majority
of data expressed as mean (standard deviation [SD]), unless
otherwise stated. Due to the low number of participants in
this sub-group analysis from China, descriptive data only are
presented in the tables to represent the entire regional pro-
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ﬁle. For hypoglycaemia change from baseline, the percentage
of people reporting at least one event was analysed using
McNemar’s test.
3. Results
3.1. Study participants
Among the 66,726 people who were enrolled in the
A1chieve study, 15,545 started insulin therapy with or
switched to detemir ± OGLDs. A total of 86.9% completed
the study treatment period, 13.1% withdrew, 7.5% lost con-
tact with their physician, 5.4% citied other reasons, and 0.2%
reported adverse drug reactions. Prior to enrolment, 4.8%
were receiving no medication for diabetes and 72.9% were
being treated with OGLDs alone. Of the remaining 22.3%
who were changing their insulin therapy, 64.4% transferred
from human insulin (sub-divided as 50.6% from NPH, 35.6%
from human premix, 8.1% from human soluble insulin, 4.2%
from basal–bolus NPH/human insulin, and the remaining
1.5% from other insulins), 26.9% transferred from the basal
insulin analogue glargine, and 8.7% transferred from other
insulin therapies. Globally, mean (±SD) duration of diabetes
was higher in the prior insulin user cohort (11.0 ± 7.0 vs.
7.6 ± 5.5 years). For insulin-naïve participants, the percent-
age of people using more than two OGLDs decreased by 58%
(27.7% pre-study, 11.7% at 24 weeks). Metformin use was
maintained (84%), but there were reductions in the percent-
ages of people using sulphonylureas (84.3% pre-study, 64.0%
at 24 weeks) and thiazolidinediones (23.6% pre-study, 11.3%
at 24 weeks). For the participants changing insulin ther-
apy, metformin use also remained consistent (∼80%), while
sulphonylurea and thiazolidinedione use decreased (61.5%
to 53.4%, and 14.0% to 9.2%, respectively. At the end of the
Table 1 – Patient numbers and characteristics by pre-study therapy and regional distribution in the insulin detemir
subgroup and entire A1chieve study population.
Demographic Insulin detemir subgroup population A1chieve study population
Global cohort Insulin-naïve Insulin- Global cohort Insulin-naïve Insulin-
experienced experienced
n (%) 15,545 (100) 12,078 (77.7) 3467 (22.3) 66,726 (100) 44,872 (67.2) 21,854 (32.8)
Gender, M/F (%) 54.1/45.9 55.0/45.0 51.3/48.7 55.6/44.4 57.3/42.7 51.9/48.1
Age (years) 54.6 (11.5) 54.0 (11.3) 56.8 (11.9) 54.0 (12.0) 53.2 (11.6) 55.6 (12.5)
Body weight (kg) 76.6 (16.3) 76.5 (16.3) 76.7 (16.3) 72.9 (15.0) 71.7 (14.4) 75.3 (15.9)
BMI (kg/m2) 28.2 (5.3) 28.2 (5.3) 28.4 (5.5) 27.1 (5.0) 26.7 (4.7) 27.9 (5.50
Duration of diabetes (years) 8.4 (6.0) 7.6 (5.5) 11.0 (7.0) 8.0 (19) 80 (19) 79 (20)
>2 OGLDs, n (%) 1608 (11.7) 1320 (12.1) 288 (10.2) 10,981 (20.1) 8971 (23.1) 2010 (12.7)
HbA1c (% [mmol/mol]) 9.5 (1.6) [80] 9.5 (1.6) [80] 9.3 (1.7) [78] 9.5 (1.7) [80] 9.5 (1.7) [80] 9.4 (1.8) [79]
Geographic region (% of cohort)
China 137 (100) 88 (64.2) 49 (35.8) 11,020 (100) 8206 (74.4) 2814 (25.6)
South Asia 3079 (100) 2608 (84.7) 471 (15.3) 22,447 (100) 18,067 (80.5) 4380 (19.5)
East Asia 4230 (100) 3195 (75.5) 1035 (24.5) 10,032 (100) 6594 (65.7) 3438 (34.3)
North Africa 1746 (100) 1250 (71.6) 496 (28.4) 4039 (100) 1969 (48.7) 2070 (51.3)
Middle East and Gulf 4474 (100) 3560 (79.6) 914 (20.4) 14,976 (100) 7501 (50.1) 7475 (49.9)
Latin America 643 (100) 405 (63.0) 238 (37.0) 1138 (100) 636 (55.9) 502 (44.1)
Russia 1236 (100) 972 (78.6) 264 (21.4) 3074 (100) 1899 (61.8) 1175 (38.2)
Data are mean (SD), unless otherwise stated.
BMI, body mass index; OGLD, oral glucose-lowering drug.
study, the percentage of previously insulin-experienced par-
ticipants using more than two OGLDs decreased from 11.5%
(pre-study) to 9.9% after 24 weeks using insulin detemir.
Baseline demographics and regional distribution are
shown in Table 1. The majority of patients starting basal
insulin or switching to insulin detemir came from the Mid-
dle East/Gulf and East Asian regions (28.8 and 27.2%, re-
spectively) (Table 1). Patient characteristics followed simi-
lar trends to the global cohort; regional differences of note
were that the majority of patients from Russia were female
(70.0%), while 65.5% from the Middle East/Gulf were male.
Overall duration of diabetes was highest in Latin American
countries and lowest in South Asia (11.6 ± 8.3 vs. 5.8 ± 4.3
years). Mean (±SD) body weight was highest at baseline in
the Middle East and Gulf region and Russia (87.3 ± 15.0 and
85.0 ± 15.4 kg) and lowest in East Asia (64.6 ± 12.1 kg). In
the prior insulin users groups, the mean duration of insulin
treatment was 3.2 ± 3.9 years for the global cohort and was
similar for most of the regions. Exceptions of note were Rus-
sia, where the mean duration of insulin treatment prior to
the start of the trial was 2.5 ± 2.7 years and Latin America,
where participants had been using insulin for 5.0 ± 5.5 years.
The majority of people were insulin-naïve in all regions
at baseline (range: 63.0% in Latin America to 84.7% in South
Asia). Of the prior insulin users, the majority transferred
from a human or analogue basal insulin regimen (64.7%).
For the overall cohort, this was approximately a 50:50 split
between basal analogue and human basal insulin but, re-
gionally, basal analogue was more frequently prescribed in
all regions except Russia and Latin America, where basal hu-
man insulin accounted for >85% of pre-study basal insulin
choice. Overall, 23.8% of prior insulin users switched from a
premix regimen (96.4% human insulin premix), which was
most popular in South Asia (49.3%).
Baseline glucose control was poor regardless of pre-study
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treatment or geographical region. Baseline HbA1c was low-
est in people switching from treatment with basal insulin
glargine (9.0 ± 1.7% [75 mmol/mol]) and highest in the
insulin-naïve cohort (9.5 ± 1.6% [80 mmol/mol]). Region-
ally, baseline HbA1c was lowest in North Africa 9.3 ± 1.7%
[78 mmol/mol]) and highest in Latin America (9.6 ± 2.2%
[81 mmol/mol]).
The most frequent reason given by physicians for intro-
ducing insulin detemir was to improve glycaemic control
(95.5%). Other reasons included: to reduce plasma glucose
variability (27.7%), reduce the risk of hypoglycaemia (23.9%),
address patient dissatisfaction with current therapy (22.3%),
control unstable diabetes (21.2%), and improve weight con-
trol (21.0%).
The prevalence of diabetic complications at baseline for
the overall cohort were as follows: cardiovascular (26.8%),
renal (28.4%), eye (26.5%), foot ulcer (4.4%), and neuropathic
(40.1%). Figures were similar for most regions with the ex-
ception of Russia, where the prevalence of diabetes-related
cardiovascular, eye, and neuropathy complications was no-
tably higher (70.3, 64.7, and 81.1% respectively). Russia was
also the only region to report similar prevalence of complica-
tions in both the insulin-naïve and prior insulin users. Dia-
betic renal complications were most prevalent in the Middle
East/Gulf region (39.2%).
3.2. Primary safety outcomes
Out of a total of 15,545 patients, seven SADRs were re-
ported by seven people; instances of hypoglycaemia were
noted in four people and hyperglycaemia in three; of these
adverse events, ﬁve instances were assessed as probably be-
ing related to treatment and two as possibly related.
3.3. Effectiveness outcomes
3.3.1. By pre-study therapy
Signiﬁcant improvements in glycaemic control were as-
sociated with insulin detemir from baseline to ﬁnal visit
in insulin-naïve patients and prior insulin users. Mean
reductions in HbA1c, FPG, and PPG were greater in the
insulin-naïve subgroup than for prior insulin users (Table 2).
Overall, the proportion of patients reaching HbA1c <7.0%
[53 mmol/mol] increased from 3.0% at baseline to 31.5% af-
ter 24 weeks; similar results were reported for the pre-study
therapy subgroups (Table 2).
In the insulin-naïve cohort, mean daily insulin dose was
0.24 ± 0.13 U/kg/day at baseline and 0.35 ± 0.18 U/kg/day
at the end of the study. In prior insulin users, the pre-study
mean insulin dose was 0.42 ± 0.24 IU/kg/day, and 0.45 ±
0.24 U/kg/day of insulin detemir at 24 weeks (Table 2). For
the 3467 prior insulin users starting insulin therapy with
detemir at baseline, the majority switched from NPH (32.6%,
n = 1131), insulin glargine (26.9%, n = 934), or premix insulin
(23.8%, n = 825).
Pre-study mean basal insulin doses were 0.38 ± 0.21
IU/kg/day (NPH) and 0.33 ± 0.17 U/kg/day (glargine); at
24 weeks insulin doses for these subgroups were 0.47 ±
0.23 U/kg/day and 0.42 ± 0.22 U/kg/day, respectively. Prior
users of premix insulin reported a mean dose change from
0.51 + 0.24 IU/kg/day to 0.46 ± 0.24 U/kg/day of insulin de-
temir at 24 weeks. Prior to switching to insulin detemir,
53.6% of patients were on a once-daily insulin regimen. At
the end of the study, 79.1% of people initiating insulin with
detemir, and 70.0% of those transferring insulin therapy to
detemir were using a once-daily regimen.
HbA1c decreased signiﬁcantly from 9.1 ± 1.8% [76 mmol/
mol] at baseline by −1.4 ± 1.7% [15 mmol/mol] (p < 0.001)
by the end of the study for NPH users, from 9.0 ± 1.7%
[75 mmol/mol] by −1.3 ± 1.7 [14 mmol/mol] for patients
switched from insulin glargine, and from 9.5% ± 1.7%
[80 mmol/mol] by −2.1 ± 1.7 [23 mmol/mol] in people chang-
ing from premix therapy (p < 0.001 for all). Signiﬁcant im-
provements (p < 0.001) were also observed for FPG and PPG:
−2.4 ± 3.6 mmol/L and −3.2 ± 4.0 mmol/L for NPH, −2.0 ±
3.3 mmol/L and −3.1 ± 4.3 mmol/L for prior insulin glargine
users, and −3.4 ± 3.2 mmol/L and −4.9 ± 4.4 mmol/L for prior
premix users, respectively.
3.3.2. Regional differences
At the end of the study, the percentage of people using a
once-daily regimen with insulin detemir ranged from 38.4%
in Russia to 88.1% in East Asia; ﬁgures were similar irrespec-
tive of prior study therapy. Mean insulin dose by region are
reported in Supplementary Table 1.1.
HbA1c decreased signiﬁcantly from baseline (p < 0.001) for
all regions, ranging from −2.2% [24 mmol/mol] in the Middle
East/Gulf region (n = 4474) to −1.4% [15 mmol/mol] in North
Africa (n = 1746). The proportion of patients reaching HbA1c
<7.0% [53 mmol/mol] ranged from 36.8% in the Middle East
and Gulf to 23.8% in North Africa. FPG and PPG values de-
creased signiﬁcantly from baseline (p < 0.0001) for all regions
(Supplementary Table 1.1), with the greatest reductions be-
ing observed in the Middle East and Gulf region (−4.2 mmol/L
FPG; −6.0 mmol/L PPG) and Latin America (−4.1 mmol/L FPG;
−6.5 mmol/L PPG).
3.4. Safety outcomes
3.4.1. Hypoglycaemia by pre-study therapy
The reported incidence of major hypoglycaemia de-
creased signiﬁcantly over 24 weeks in both the insulin-naïve
and prior insulin user subgroups (p < 0.0001). For people
changing insulin to treatment with insulin detemir, signiﬁ-
cant reductions were also reported in the incidence of over-
all, minor, and nocturnal events (p < 0.0001 for all) (Fig. 1).
The change in the incidence of overall hypoglycaemia from
baseline to 24 weeks was from 12.44 to 2.26 events per
patient-year for people previously treated with NPH, from
5.08 to 2.38 events per patient-year for prior insulin glargine
users, and from 8.08 to 1.14 events per patient year for peo-
ple switching from premix insulin.
3.4.2. Hypoglycaemia by region
A reduction in the incidence of hypoglycaemic events was
reported for all regions, but baseline values and the degree
of the reduction varied greatly (Supplementary Table 1.2).
Baseline rates for major hypoglycaemic events were highest
in North Africa and Latin America (0.59 and 0.53 events per
patient-year in 2.7 and 1.9% of the regional populations, re-
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Table 2 – Outcome measures by pre-study therapy in the insulin detemir subgroup and entire A1chieve study population.
Outcome measure Insulin detemir subgroup population A1chieve study population
Global cohort Insulin- Insulin- Global cohort Insulin- Insulin-
naïve experienced naïve experienced
Insulin dose (U/kg/day) n 15,545 12,078 3467 66726 44872 21854
Pre-study 0.42 (0.24) – 0.42 (0.24) 0.55 (0.29) – 0.55 (0.29)
Baseline 0.27 (0.15) 0.24 (0.13) 0.35 (0.19) 0.44 (0.24) 0.38 (0.20) 0.55 (0.27)
Week 24 0.37 (0.20) 0.35 (0.18) 0.45 (0.24) 0.50 (0.26) 0.44 (0.22) 0.62 (0.30)
HbA1c (% [mmol/mol]) n 10,581 8459 2122 44,661 30, 369 14,292
Baseline 9.5 (1.6) [80] 9.5 (1.6) [80] 9.3 (1.7) [78] 9.5 (1.7) [80] 9.5 (1.7) [80] 9.4 (1.8) [79]
Week 24 7.5 (1.2) [58] 7.4 (1.1) [57] 7.6 (1.3) [60] 7.4 (1.1) [57] 7.4 (1.0) [57] 7.6 (1.2) [60]
Change −2.0 (1.6) [22] −2.1 (1.6) [23] −1.6 (1.7) [17] −2.1 (1.7) [23] −2.2 (1.7) [23] −1.8 (1.7) [19]
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
People reaching HbA1c <7.0% n 13,190 (100.0) 10,376 (100.0) 2814 (100.0) 57,250 (100.0) 38,639 (100.0) 18,611 (100.0)
[53 mmol/mol] (%) Baseline 3.0 2.1 6.2 3.9 3.0 5.6
Week 24 31.5 31.7 30.3 31.8 32.0 31.3
FPG, pre-breakfast (mmol/L) n 10742 8560 2182 48,191 33,087 15,104
Baseline 10.9 (3.3) 11.2 (3.2) 9.9 (3.3) 10.9 (3.5) 11.2 (3.4) 10.5 (3.7)
Week 24 7.1 (2.0) 7.0 (1.9) 7.3 (2.3) 7.1 (1.9) 7.1 (1.8) 7.2 (2.2)
Change −3.9 (3.3) −4.2 (3.2) −2.6 (3.5) −3.8 (3.5) −4.1 (3.3) −3.2 (3.8)
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
PPG (mmol/L), post-breakfast n 7148 5757 1391 33,742 23,334 10,408
Baseline 14.8 (4.2) 15.0 (4.2) 13.8 (4.3) 15.1 (4.4) 15.5 (4.3) 14.2 (4.5)
Week 24 9.6 (2.9) 9.5 (2.8) 9.9 (3.2) 9.7 (2.9) 9.8 (2.9) 9.7 (3.0)
Change −5.1 (4.3) −5.5 (4.2) −3.8 (4.3) −5.4 (4.5) −5.8 (4.4) −4.5 (4.6)
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Body weight (kg) n 11,934 9336 2598 50,059 33,716 16,343
Baseline 76.6 (16.3) 76.5 (16.3) 76.7 (16.3) 73.3 (14.8) 72.1 (14.3) 75.7 (15.7)
Week 24 76.2 (15.5) 76.2 (15.4) 76.0 (15.7) 73.3 (14.1) 72.2 (13.5) 75.7 (15.1)
Change −0.4 (4.0) −0.3 (4.0) −0.7 (3.6) 0.1 (3.7) 0.1 (3.7) −0.0 (3.6)
p-value <0.001 <0.001 <0.001 <0.001 <0.001 0.081
SBP (mmHg) n 11,620 9077 2543 45,285 29,595 15,690
Baseline 133.2 (16.7) 133.3 (16.7) 133.0 (16.9) 134.2 (17.8) 134.0 (17.7) 134.7 (18.0)
Week 24 128.0 (14.9) 127.9 (15.2) 128.4 (13.7) 127.9 (13.5) 127.3 (13.3) 129.0 (13.7)
Change −5.2 (17.3) −5.4 (17.7) −4.5 (15.6) −6.3 (17.1) −6.6 (17.4) −5.7 (16.6)
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Total cholesterol (mmol/L) n 5791 4529 1262 20, 293 11,994 8299
Baseline 5.3 (1.3) 5.3 (1.2) 5.2 (1.4) 5.3 (1.3) 5.4 (1.3) 5.2 (1.3)
Week 24 4.8 (1.0) 4.8 (0.9) 4.8 (1.0) 4.8 (1.0) 4.8 (1.0) 4.8 (1.0)
Change −0.5 (1.1) −0.6 (1.1) −0.4 (1.1) −0.5 (1.2) −0.6 (1.2) −0.4 (1.2)
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
HDL cholesterol (mmol/L) n 4388 3418 970 17,306 10,189 7117
Baseline 1.1 (0.4) 1.1 (0.4) 1.1 (0.4) 1.1 (0.4) 1.2 (0.4) 1.1 (0.4)
Week 24 1.2 (0.4) 1.2 (0.3) 1.2 (0.4) 1.2 (0.4) 2.7 (0.4) 1.2 (0.4)
Change 0.0 (0.4) 0.0 (0.3) 0.0 (0.4) 0.1 (0.4) 0.1 (0.4) 0.0 (0.4)
p-value <0.001 <0.001 0.012 <0.001 <0.001 <0.001
LDL cholesterol (mmol/L) n 4428 3459 969 17,494 10,304 7190
Baseline 3.1 (1.0) 3.1 (1.0) 3.0 (1.0) 3.1 (1.0) 3.2 (1.0) 3.1 (1.1)
Week 24 2.7 (0.8) 2.7 (0.8) 2.7 (0.9) 2.8 (0.9) 2.7 (0.9) 2.8 (0.9)
Change −0.4 (1.0) −0.4 (1.0) −0.3 (0.9) −0.4 (1.0) −0.4 (1.0) −0.3 (0.9)
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Triglycerides (mmol/L) n 5413 4251 1162 19,856 11,672 8184
Baseline 2.1 (1.0) 2.1 (1.0) 1.9 (1.0) 2.1 (1.1) 2.1 (1.1) 2.0 (1.1)
Week 24 1.7 (0.7) 1.7 (0.7) 1.7 (0.8) 1.8 (0.7) 1.7 (0.7) 1.8 (0.7)
Change −0.3 (0.9) −0.4 (0.9) −0.2 (0.9) −0.3 (0.9) −0.4 (1.0) −0.3 (0.9)
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Data are mean (SD) unless otherwise stated.
FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PPG, postprandial plasma glucose; SBP, systolic
blood pressure.
spectively). South Asia reported the lowest baseline values,
with 0.08 events per patient-year in 0.5% of the regional
population (Supplementary Table 1.2). Overall, minor, and
nocturnal hypoglycaemic events were observed to be high-
est at baseline in North Africa, Latin America, and Russia,
while all three regions observed a decrease in the events per
patient-year. Russia, unlike the other two regions, did not
observe a signiﬁcant decrease in the percentage of patients
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Fig. 1 – Changes in the incidence of hypoglycaemia in insulin-naïve and prior insulin users after 24 weeks of treatment
with insulin detemir ± oral glucose-lowering drugs.
experiencing these events. South Asia reported the lowest
incidence of overall and minor events at baseline, which
were signiﬁcantly reduced in the region at the end of the
study (Supplementary Table 1.2).
3.5. Secondary clinical outcome measures
3.5.1. By pre-study therapy
The mean change in body weight over 24 weeks for all
patients treated with insulin detemir was −0.4 ± 4.0 kg
(p < 0.001). Both insulin-naïve and prior insulin user sub-
groups reported a reduction in body weight (Table 2). Mean
change in body weight at 24 weeks was −0.6 ± 3.2 kg for the
prior NPH users, −0.4 ± 3.9 kg for prior glargine users, and
−1.0 ± 3.6 kg for people previously treated with premix in-
sulin (p < 0.001 for all). Mean SBP decreased signiﬁcantly
for the entire cohort (−5.2 ± 17.3 mmHg; p < 0.001) to
128.0 ± 14.9 mmHg by the end of the study and in both
pre-study therapy subgroups (Table 2). Mean blood lipid
proﬁles improved overall by −0.5 ± 1.1 mmol/L; there was
no clinically meaningful change in high-density lipopro-
tein (HDL) cholesterol, but low-density lipoprotein choles-
terol (LDL) values fell by −0.4 ± 1.0 mmol/L and triglycerides
by −0.3 ± 0.9 mmol/L (p < 0.001) (Table 2). There were no
notable differences between the insulin-naïve and insulin
experienced subgroups.
3.5.2. Regional differences
Five of the seven regions observed a reduction in mean
body weight (China, South Asia, Middle East and Gulf, Rus-
sia and Latin America; see Supplementary Table 1.1). Mean
SBP decreased in all regions. The largest decrease was ob-
served in Russia (−8.5 ± 13.7 mmHg; p < 0.001), where
mean baseline values were the highest of any participat-
ing region (141.2 ± 16.3 mmHg), with the smallest reduc-
tion being reported in North Africa (−1.6 ± 24.2 mmHg;
p = 0.012). Total cholesterol values at baseline ranged be-
tween 4.6 ± 1.1 mmol/L (North Africa) and 6.0 ± 1.2 mmol/L
(Russia). Reductions were reported for all regions between
−0.2 ± 1.2 mmol/L (North Africa) and −0.6 ± 1.3 mmol/L
(East Asia) and −0.6 ± 1.0 mmol/L (Middle East and Gulf).
HDL cholesterol values remained generally unchanged as
reported for the overall cohort, and all regions reported a
decrease in LDL cholesterol and triglyceride levels (Supple-
mentary Table 1.1). The degree of reduction in blood lipid
proﬁle values observed regionally did not appear to be re-
lated to the baseline value.
4. Health-related quality of life
HRQoL scores improved signiﬁcantly irrespective of pre-
study therapy (p < 0.001). For all users of insulin detemir, the
self-assessed VAS rating (0–100) increased by +14.3 points:
+15.2 points in the insulin-naïve subgroup and +10.9 points
for prior insulin users. Scores at baseline were similar for the
overall cohort and in the insulin-naïve and prior insulin user
subgroups (62.6, 62.1, and 64.3, respectively).
HRQoL scores at baseline varied between regions. South
Asia and Russia reported the lowest scores of 55.4 and 56.0
points; North Africa, Latin America, and East Asia had base-
line scores between 63.3 and 68.5 points; and the Middle
East and Gulf region had the highest pre-study score of
71.2 points. HRQoL improved signiﬁcantly by week 24 in all
regions (p < 0.001). The degree of improvement in HRQoL
varied from +22.4 points on the VAS scale in South Asia to
+8.3 points in East Asia.
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5. Discussion
Clinically and statistically signiﬁcant improvements in
HbA1c, FPG, and PPG were observed in people with T2D
either starting insulin therapy with or changing to insulin
detemir as part of the A1chieve study. These improvements
in glycaemic proﬁle were reported consistently across all
participating regions and irrespective of prior treatment reg-
imen. The improvements in glycaemic control were accom-
panied by reduced rates of major hypoglycaemia, low rates
of SADRs, improved patient perception of HRQoL, and the
absence of clinically signiﬁcant increase in body weight. Us-
ing Tables 1 and 2, these ﬁndings can be directly compared
against those from the entire A1chieve study population.
The majority of people starting insulin detemir were
insulin-naïve at baseline and reported greater improvements
in HbA1c (−2.1% [23 mmol/mol]) than participants changing
insulin therapy (−1.6% [17 mmol/mol]), despite similar base-
line values. This is consistent with data previously reported
for insulin detemir from observational studies and RCTs
of basal-only insulin replacement in insulin-naïve people
with T2D. Comparable results were also seen with regards to
the change in number of hypoglycaemic events and modest
weight loss [12,14,15,18,20,23,24]. Improvements in FPG and
PPG were also greater in the insulin-naïve subgroup; how-
ever, mean baseline values were higher than those reported
for insulin-experienced people.
In insulin-experienced people, mean HbA1c was reduced
by 1.6% [17 mmol/mol], a similar change to data previously
reported for patients switching to detemir [19,20]. This may
be a result of the very poor level of glycaemic control at
baseline, not only in this treatment cohort but for the entire
A1chieve study population, for whom a reduction of 1.8%
[19 mmol/mol] was reported [7]. Signiﬁcant improvements
in all measures of glycaemic control were seen regardless
of prior insulin regimen, human or analogue, which sup-
ports previous ﬁndings from a clinical practice [19]. The
proportion of patients reaching HbA1c <7.0% [53 mmol/mol]
with insulin detemir ± OGLDs was ∼30%, irrespective of pre-
study therapy; similar to that reported for the entire A1chieve
study cohort (31.8%) [7] and for basal insulin analogue ther-
apy in RCTs [25,26]. Likewise, overall mean reductions in FPG
and PPG reported at the end of the study (−3.9 ± 3.3 and
−5.1 ± 4.3 mmol/L, respectively) are comparable to those
seen for the entire A1chieve cohort (−3.8 ± 3.5 mmol/L; p <
0.001 and −5.4 ± 4.5 mmol/L; p < 0.001, respectively) [7], sug-
gesting that statistically signiﬁcant improvements in blood
glucose control are universal with insulin analogue therapy,
irrespective of prior insulin regimen.
Regionally, both the poor level of glycaemic control at
baseline and the magnitude of improvement were remark-
ably consistent. The proportion of patients attaining HbA1c
<7.0% [<53 mmol/mol] varied considerably (Supplementary
Table 1.1). China reported the lowest baseline HbA1c of 8.4 ±
1.7% [68 mmol/mol] but too few patients started a regimen
with insulin detemir in the region (n = 137) to be considered
in the regional comparison. This low number was due to the
fact that insulin detemir was not available in China during
patient recruitment, and only gained marketing approval to-
wards the end of the study. This exclusion from the regional
comparison is unfortunate as, in the entire A1chieve study
population, patients in China reported the largest reduction
in HbA1c (2.5% [28 mmol/mol]) [7] and it would have been
interesting to see if this trend was consistent in patients
initiated on insulin detemir
Insulin-experienced people reported signiﬁcant reduc-
tions in the rate of overall, major, minor, and nocturnal
hypoglycaemic events, while insulin-naïve patients, not un-
expectedly, reported a reduction in the rate of major events
only. The incidences of overall, minor, and nocturnal hypo-
glycaemic events were highest in Latin America and Russia
at baseline, yet, despite similar improvements in glycaemic
control and a comparative daily insulin dose after 24 weeks
of treatment with insulin detemir, reductions in the event
rates and the percentage of people experiencing hypogly-
caemic events was markedly different between the two
regions. There are a number of non-drug hypoglycaemia-
precipitating factors that may inﬂuence this reported out-
come, such as manual work, alcohol consumption, nutri-
tional differences, patient age, and degree of insulin resis-
tance. However, despite regional differences, a reduction in
the incidence of hypoglycaemic events was observed, which,
for such a heterogeneous population, may result from study-
related improvement in self-management, although the ob-
servation is consistent with previous publications [7,14–
17,19,20,23].
A modest reduction in body weight was observed in both
pre-study therapy subgroups, in contrast to the weight gain
that is usually associated with insulin initiation. This ev-
idence supports previously published data associating in-
sulin detemir with minimal weight change (14,15,17,18,27).
Changes in weight reported by region were minimal, with
greater signiﬁcant reductions being observed where reduc-
tions in HbA1c were greater, rather than a higher base-
line weight. As the majority of the people from all re-
gions were insulin-naïve at baseline, weight change ranging
between −1.1 and +0.5 kg is modest considering the geo-
graphical and lifestyle differences. Interestingly, in the entire
A1chieve study population, although no clinically signiﬁcant
weight change was reported, a larger range was seen (−0.8
and +0.9 kg) [7]. Changes in SBP and blood lipid proﬁles
were also favourable for both the insulin-naïve and insulin-
experienced subgroups, which reﬂects the results seen for
the entire A1chieve study cohort [7].
The A1chieve study, by nature of its design, has a number
of limitations that must be considered when interpreting the
data [7]. Results can be difﬁcult to conclude due to the het-
erogeneity of the population and healthcare systems encom-
passed by the geographical reach of the study. The lack of a
control group reduces certainty that results are attributable
to the insulin treatment alone. The consulting physicians
may have initiated confounding interventions at the same
time as the decision to start treatment with the study in-
sulin, and the level of education in diabetes management
provided, especially for the 73% of patients included in this
analysis who were previously insulin-naïve, may have inﬂu-
enced the outcomes for the duration of the study follow-up
period. Additionally, the duration of the study was relatively
short, thus the observed beneﬁcial ﬁndings may, in part, be
due to an ‘entry into study’ effect that may not be sustain-
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able in the long term. A small percentage of people were
switched from basal–bolus treatment to basal insulin, which
may not have been the ideal course of treatment optimi-
sation. Certain endpoints were dependant on patient recall
diaries and records, which may subject the data to recall
bias. Despite limitations that are inherent in any observa-
tional study design, observational studies can help to assess
treatment effects in diverse patient groups in different clin-
ical environments and broaden the clinical evidence base
provided by RCTs.
6. Conclusion
People with T2D in poor glycaemic control who started
treatment with insulin detemir in routine clinical care re-
ported signiﬁcant improvements in glycaemic control ir-
respective of prior treatment and geographical region af-
ter 24 weeks. These improvements were achieved without
any safety or tolerability complications, and were associated
with an improvement in patient self-assessment of HRQoL.
These safety and effectiveness data for insulin detemir in
the A1chieve study are consistent with those from previ-
ous study publications. The addition of evidence from pre-
dominantly less well-resourced countries expands the global
picture of the role insulin detemir fulﬁls in real-life clinical
practice.
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